The historical rank and industry rank for Zevra Therapeutics's Net Margin % or its related term are showing as below:
ZVRA'
s Net Margin % Range Over the Past 10 Years
Min: -263.48 Med: -167.69 Max: -29.86
Current: -181.76
ZVRA's Net Margin % is ranked worse than 52% of 1025
companies
in the Biotechnology industry
Industry Median: -151.78
vs ZVRA: -181.76
Zevra Therapeutics Net Margin % Historical Data
The historical data trend for Zevra Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zevra Therapeutics's Net Margin %
For the Biotechnology subindustry, Zevra Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Net Margin % falls into.
Zevra Therapeutics Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Zevra Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (NAS:ZVRA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Zevra Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Zevra Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Zevra Therapeutics (Zevra Therapeutics) Business Description
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVRA has been successfully added to your 